Table 4.
Baseline characteristics of subjects prior to first treatment with budesonide HFA and CFC pMDIs
| Variable | Before HFA | Before CFC |
|---|---|---|
| Age (years)* | 40.0 (14.13) | 39.5 (14.65) |
| Sex (male : female) | 20:24 | 19:26 |
| Race (Caucasian : Black : Oriental : other) | 42:0:1:1 | 42:0:0:3 |
| Methacholine PC20 (mg ml−1) | 0.68 (0.33–1.03) | 0.62 (0.31–0.93) |
| Exhaled nitric oxide (parts per billion) | 34.42 (23.62–45.22) | 34.76 (25.13–44.39) |
| Spirometry | ||
| FEV1 (l) | 2.86 (2.62–3.10) | 2.80 (2.55–3.05) |
| FVC (l) | 3.83 (3.50–4.16) | 3.75 (3.42–4.08) |
| FEF25–75 (l) | 2.47 (2.15–2.79) | 2.42 (2.09–2.75) |
| PEF (l min−1) | 445.25 (408.97–481.53) | 438.80 (402.54–475.06) |
| Cortisol/creatinine ratio (nmol mmol−1) | 3.49 (2.40–4.58) | 3.50 (2.35–4.65) |
*
Data are presented as arithmetic mean (SD). Data are presented as geometric mean (95% confidence interval) unless otherwise indicated. Baseline values are shown after washout before each randomized treatment period. FEF25–75, forced expiratory flow between 25 and 75% of forced vital capacity; FEV1, forced expiratory volume in 1 s; PC20, concentration of methacholine required to produce a 20% decrease in FEV1; FVC, forced vital capacity; PEF, peak expiratory flow.